文献速递瓣膜病与结构性心脏病

风湿性主动脉瓣狭窄患者的经导管主动脉瓣植入术

Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis.
PubMed 文献 · Heart · 2022-07-13

本研究基于前瞻性TAVI注册研究,识别出105例风湿性主动脉瓣狭窄患者,并按1:4倾向性评分匹配至退行性主动脉瓣狭窄患者。结果显示,在匹配队列中风湿性AS患者30天和1年心血管死亡率均低于退行性AS患者,技术成功率与未匹配队列中两组相当。结论提示TAVI对经过选择的老年风湿性AS患者可能是安全有效的治疗策略。

要点

  • 风湿性AS患者占TAVI注册人群的4.5%,女性更多、年龄更大、外科风险更高且多瓣膜病更常见。
  • 匹配队列中风湿性AS患者30天心血管死亡率1.9% vs 8.9%,1年10.0% vs 20.3%,均低于退行性AS。
  • 未匹配队列中两组技术成功率与1年心血管死亡率无显著差异。

核心结论

  • TAVI可能对经过选择的老年风湿性主动脉瓣狭窄患者是安全有效的治疗策略。

研究设计与样本

  • 前瞻性TAVI注册研究,共2329例接受TAVI患者,其中105例(4.5%)为风湿性AS。
  • 风湿性AS依据ICD-10编码和/或急性风湿热病史和/或世界心脏联盟超声诊断标准识别。
  • 风湿性AS患者按1:4倾向性评分匹配至退行性AS患者。

主要发现

  • 与退行性AS相比,风湿性AS患者更常见女性、年龄更大、外科风险更高且多瓣膜病更常见。
  • 未匹配队列中,风湿性AS与退行性AS的技术成功率分别为85.7%与85.9%(p=0.887)。
  • 未匹配队列中,1年心血管死亡率分别为10.0%与8.6%(HR 1.16,95%CI 0.61-2.18,p=0.656)。
  • 匹配队列中,风湿性AS患者30天心血管死亡率为1.9% vs 8.9%(调整HR 0.18,95%CI 0.04-0.80,p=0.024)。
  • 匹配队列中,风湿性AS患者1年心血管死亡率为10.0% vs 20.3%(调整HR 0.44,95%CI 0.24-0.84,p=0.012)。

临床怎么用

  • 对于经过选择的老年风湿性主动脉瓣狭窄患者,TAVI可作为治疗选择之一。
  • 风湿性AS患者常合并多瓣膜病且外科风险较高,TAVI决策需综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatic heart disease (RHD) accounts for the highest number of deaths from valvular heart disease globally. Yet, rheumatic aortic stenosis (AS) was excluded from landmark studies investigating the safety and efficacy of transcatheter aortic valve implantation (TAVI). We aimed to describe the clinical and anatomical characteristics of patients with rheumatic AS undergoing TAVI, and to compare procedural and clinical outcomes with patients undergoing TAVI for degenerative AS. METHODS: In a prospective TAVI registry, patients with rheumatic AS were identified based on International Classification of Diseases version 10 codes and/or a documented history of acute rheumatic fever and/or the World Heart Federation criteria for echocardiographic diagnosis of RHD, and were propensity score-matched in a 1:4 ratio to patients with degenerative AS. RESULTS: Among 2329 patients undergoing TAVI, 105 (4.5%) had rheumatic AS. Compared with patients with degenerative AS, patients with rheumatic AS were more commonly female, older, had higher surgical risk and more commonly suffered from multivalvular heart disease. In the unmatched cohort, both technical success (85.7% vs 85.9%, p=0.887) and 1-year cardiovascular mortality (10.0% vs 8.6%; HR 1.16, 95% CI 0.61 to 2.18, p=0.656) were comparable between patients with rheumatic and degenerative AS. In contrast, patients with rheumatic AS had lower rates of 30-day and 1-year cardiovascular mortality compared with matched patients with degenerative AS (1.9% vs 8.9%, adjusted HR (HRadj) 0.18, 95% CI 0.04 to 0.80, p=0.024; and 10.0% vs 20.3%, HRadj 0.44, 95% CI 0.24 to 0.84, p=0.012, respectively). CONCLUSION: TAVI may be a safe and effective treatment strategy for selected elderly patients with rheumatic AS. TRIAL REGISTRATION NUMBER: NCT01368250.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Okuno T, Tomii D, Buffle E, et al. Transcatheter aortic valve implantation in patients with rheumatic aortic stenosis. Heart. 2022. PMID: 35351823. doi:10.1136/heartjnl-2021-320531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。